GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Minority Interest

Lirum Therapeutics (Lirum Therapeutics) Minority Interest : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Lirum Therapeutics's minority interest for the quarter that ended in Dec. 2023 was $0.00 Mil.

Lirum Therapeutics Minority Interest Historical Data

The historical data trend for Lirum Therapeutics's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics Minority Interest Chart

Lirum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Minority Interest
- - -

Lirum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Sep23 Dec23
Minority Interest - - - - -

Lirum Therapeutics Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Lirum Therapeutics (Lirum Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Minority Interest
Comparable Companies
Traded in Other Exchanges
N/A
Address
590 Madison Avenue, 21st Floor, New York, NY, USA, 10022
Website
https://www.lirumtx.com
Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines